MedPath

A study to identify the optimal preemptive analgesic dose of gabapenti

Phase 4
Conditions
Health Condition 1: O- Medical and Surgical
Registration Number
CTRI/2023/10/058395
Lead Sponsor
ourdes hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) ASA 1 and 2 patients undergoing elective lumbar laminectomy under general anesthesia

Exclusion Criteria

1) ASA 3 and 4

2) Pregnant and lactating patients

3) Patients on maintenance dose of gabapentin for any indication

4) Emergency surgery

5) Drug allergy to gabapentin or any common drugs that are used during general anesthesia

6) Prolonged surgery more than 4 hours

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath